Patients and Methods:
Aerosolized liposomal amphotericin B (lipAmB) was evaluated as an antifungal prophylaxis in patients with an expected neutropenia of more than 10 days due to intensive chemotherapy or stem cell transplantation, in a prospective phase II trial. Results: 98 treatment episodes were included in the study and compared to 105 historical control patients. Inhalation was performed between 0 and 103 days. No severe side effects of therapy occurred. 40 patients considered inhalations as unpleasant, 2 as very unpleasant, mostly due to bad taste or cough. Few cases of definite or probable IFI were recorded, whereas a large number of patients were treated with systemic antifungal therapy for pneumonia or fever of unknown origin without a significant difference between study patients and controls. In a predefined subgroup analysis of 48 patients with newly diagnosed acute myeloid leukemia (AML), significantly more patients survived for 1 year in the AmB prophylaxis than in the control group (80% vs. 54%, p < 0.01). Conclusions: Inhalations of lipAmB are feasible and safe. Results in the subgroup of patients with AML together with data from other trials suggest further evaluation of effectiveness.
Introduction
Invasivefungalinfections(IFI)arewell-recognizedcomplications in patients with hematologic malignancies [1] [2] [3] . Individual risk of IFI increases with profound neutropenia of prolonged duration, i.e. more than 10 days. Clinical outcomes in leukemia patients with additional clinically apparent IFI are significantly inferior to outcomes in patientssufferingfromleukemiaalone.Candidainfectionsas onetypeofIFItaketheiroriginmainlyfromgastrointestinal infectionsandcanbeeffectivelyreducedbyprophylaxiswith fluconazole, although this strategy has only formally been showntobeeffectiveinpatientsafterallogeneictransplantation.ThemajorityofIFIdevelopinthelung,withAspergillus as the most frequent pathogen, and it can be assumed thattheseinfectionsoriginatefrominhaledconidia. Aprophylacticstrategyusingnebulizedantifungalagents thereforeseemstobearationalapproach.AmphotericinB deoxycholate (AmBd) was tested earlier for this purpose. Although initial phase II studies showed promising results, in a formal phase III study, AmBd did not improve outcomes of high-risk patients in comparison to placebo [4] . However, based on preclinical models, liposomal AmB (lipAmB) may be better tolerated and more effective than AmBdduetothefollowingreasons:UnlikeAmBd,lipAmB doesnotfoamduringnebulization,resultinginamoreuniformformationofsmalldroplets;inaddition,lipAmBdoes notinhibitthefunctionofpulmonarysurfactantsasreported for AmBd [5] and, in animal models of pulmonary aspergillosis, lipAmB or AmB lipid complex was more effective thanAmBd [6] [7] [8] [9] .Furthermore,nebulizedlipAmBorAmB lipid complex was successfully used in previous small publishedcaseseriesinpatients [10, 11] andfurtherunpublished studiesandwasthereforesystematicallytestedinoursingleinstitutionphaseIIstudydescribedbelow.
Patients and Methods

Study Design
Nebulized lipAmB was evaluated in a phase II trial in patients with expectedneutropenia(<0.5G/l)ofmorethan10daysduetoinduction and/orconsolidationchemotherapyforacuteleukemiasand/orallogeneic stem cell transplantation. The patients did not have to be included upfrontbeforeenteringtheirfirstchemotherapycyclebutcouldalsobe includedduringsubsequentcycles,providedthatthenextchemotherapy would lead to profound neutropenia and that no systemic mould-active drug had already been given. Fluconazole prophylaxis was allowed and wasusedinthevastmajorityofpatientsaccordingtolocalcommonpractice at 400 mg/day throughout the whole study period, in patients andcontrols.Apatientcouldenterthestudyforasecondtimeasa'new' patient(e.g.duringtherapyofarelapseofhis/herleukemia)ifmorethan 3monthshadpassedsincethelastlipAmBinhalation.
Prophylaxis consisted of lipAmB (Ambisome ® , Gilead, Foster City, CA,USA)nebulizedbytheuseofjetstreamnebulizers(LCStar,Pari, Starnberg, Germany). LipAmB was reconstituted with distilled water as for regular intravenous (i.v.) use and applied undiluted in doses of 12.5 mg on 4 consecutive days and then twice weekly until neutrophil recovery. Inhalations were supervised by physiotherapists, a single application taking 10-20 min. Treatment was paused with recovery of neutrophils>1G/landresumedduringneutropenicepisodesfollowing subsequent chemotherapy cycles. If systemic mould-active antifungals werestarted due to suspectedIFIin an individual patient, per-protocol lipAmBinhalationswerestopped,butinhalationscouldbecontinuedat the discretion of the treating physician. Management of suspected IFI was not specified in the protocol, although some recommendations for diagnosticworkupweregiven.Computedtomography(CT)scansofthe chest and serum Aspergillus antigen tests were recommended in fever refractory to antibacterial therapy. The patients were interviewed for possiblesideeffectsofinhalationsinregularintervals. TheprotocolwasapprovedbytheethicscommitteeoftheUniversity of Regensburg. All patients gave their written informed consent before inclusioninthestudy.
Patient Population
Patientswerescreenedforeligibilityfrom07/2003untilthetargetnumber of100treatmentepisodeswasreached.Patientsfulfillingthesameentry criteriaandtreatedinthesameinstitutionintheyears2000-2002served ashistoricalcontrols [12] .
Study Analysis
Evaluationoftoxicityandapossiblereductionintheincidenceofproven or probable fungal infections according to published consensus criteria [13] weredefinedasprimaryoutcomeparameters.Predefinedsecondary outcomeparameterswereincidenceoffeverofunknownoriginrefractorytoantibacterialtherapyformorethan72h,delaysofchemotherapy inpatientswithAML,and1-yearsurvivalwithinthesubgroupofnewly diagnosedAMLpatients.
Results
From07/2003to10/2005,101coursesoflipAmBprophylaxis in 96 independent patients were included in the study. 3 of these were not eligible because systemic mould-active antifungaltherapyhadalreadybeeninitiatedatstudyentry.The remaining 98 eligible cases were analyzed by intent-to-treat principles. The majority of patients received chemotherapy for acute leukemia; 43 patients were treated by transplantationofallogeneicbonemarroworbloodstemcells.Acorresponding sample of patients that would have met inclusion criteria was analyzed for control purposes. Further patient characteristicsaregivenintable1.Baselinecharacteristicsfor age, sex, and fraction of allogeneic transplants were rather similar between study patients and controls, with the exception of myeloproliferative diseases (mainly chronic myeloid leukemia(CML))thatwereonlypresentinthecontrolgroup.
10patientsneverstartedinhalationduetogeneralfatigue, patientrequest,orstartofsystemicantifungaltherapy;46pa-tients remained on therapy per protocol until neutrophil recoveryafterthelastplannedchemotherapycycleoruntilstart ofsystemicantifungaltherapy,andin41patientsinhalations were either stopped prematurely or not restarted in subsequentchemotherapies(13patients),mainlyduetotherequest ofpatientsfeelinguncomfortableduringtheinhalationprocedure.In1patient,theexacttimingandreasonfordiscontinu-ationwasunfortunatelynotdocumented.Discountingbreaks ofstudytherapyduringperiodsofneutrophilrecovery,inhalationwasperformedbetween0and103dayswithameandura-tionof32days,andamediandurationof26days(table2).
Noseveresideeffectsoftherapylikefeveroracutedyspneaoccurredandnopulmonaryinfiltratesorothersymptoms duringfurtherfollow-upwhereconsideredtobeprovokedby lipAmBinhalations.40patientsconsideredinhalationasun- pleasant, 2 as very unpleasant, mostly due to bad taste or cough. All side effects can therefore be specified as grade I according to common toxicity criteria (CTC). Few cases of definite or probable IFI were recorded, whereas a large number of patients were treated with systemic antifungal therapy for possible IFI, unspecific pneumonia, or fever refractorytoantibacterialdrugs,withoutasignificantdifference betweenstudypatientsandcontrols(table2).Inananalysis
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During data analysis of patients and controls, we could define only very few proven or probable IFI. Methods for thedetectionofIFIarenotsensitive,andmanycasesofIFI are hidden behind 'fever of unknown origin', 'unspecific' pulmonary infiltrates or 'possible fungal infection' [14, 15] . Forthisreason,earlyantifungalinterventionswithoutclearcutevidenceofafungalinfectionarecommonpractice,becauseanundetectedanduntreatedIFImayrapidlybecome life-threatening. This strategy is also supported by a recent publication [16] .Inourpatients,systemicantifungaltherapy wasfrequentlyappliedempiricallybytreatingphysiciansin ambiguoussituations.ForstudiesofIFIprophylaxisorearly intervention, stringent diagnostic workup schedules using frequent determination of serum Aspergillus antigen and high-resolutionCTscanswithdefineddiagnosticcriteriaare helpful;however,unfortunatelythesecriteriahavenotbeen definedinsuchastrictmannerinourprotocolanddiagnosticshavebeensomewhatsparserintheearliercontrolgroup. However, even in recent clinical trials with standardized diagnostics,largepatientnumberswereneededtoshowthe advantageofaprophylacticantimycoticstrategy,inthatcase oralposaconazolesolution [17] .Therefore,inretrospect,the absence of a significant difference in proven and probable IFIbetweenthestudyarmandthehistoricalcontrolisnot surprising.Inaddition,theresultsmayalsobebiasedagainst a positive result of our study by a somewhat increasing empiricaluseofantifungalsinourinstitutionoverthestudy period.ThisismainlyduetotheincreasinguseofCTscans allowingearlierandmoresensitivedetectionofpulmonary infiltratesandduetotheapprovalofvoriconazolewhichis applied more generously due to fewer side effects when comparedtosystemicAmBd.
Data from our preplanned subgroup analysis in AML patients showing an improvement in survival compared to historical controls are more positive, but of course have to be interpreted with great caution. Confounding is possible usinghistoricalcontrolsinaretrospective,non-randomized study. No obvious differences in the management of AML between the treated patients and historical controls were introduced in our institution, except for the use of voriconazole that was already available for the intervention group but not for the control group, as described above. AML patients in the intervention group were somewhat youngerthanthoseinthehistoricalcontrolcohort,andthe rate of allogeneic transplantation in AML patients in the treatedcohortwashigherthaninthecontrols.Thesedifferencesmaybeindicatorsofbiasduetodifferentpatientcharacteristics.Allogeneictransplantationmayalsohaveafavorableimpactonmortalitybyitself;however,thedifferencein numbers of allogeneic transplantations is smaller than the differenceinmortality.Analysisofthecausesofdeathmay bemisleadingfortworeasons:Firstly,someofthepatients were treated outside our institution after completion of induction and consolidation chemotherapy and information conducted ex post, we analyzed possible differences in outcomebetweenpatientsstrictlyadheringtotheinhalationprotocolandothers:Ofthe10patientsneverstartinginhalation, systemicantifungalswereinitiatedinall10(100%),of41pa-tients prematurely terminating inhalations, antifungals were startedin28(68%),andinper-protocolpatients,antifungals wereusedin29(63%),pointingtoapossibleprotectiveeffect inprotocoladherers.
Weevaluatedthe1-yearsurvivalofnewlydiagnosedAML patientsinapredefinedsubgroupanalysis(table3).Studypatientswere,onaverage,somewhatyoungerandtransplanted morefrequently.IntheseAMLpatients,80%inthelipAmB prophylaxisgroupsurvivedfor1year,significantlymorethan in the control group (54%). 3 AML patients were lost to follow-up for this analysis because they had moved out of ourarea.Ofthedeceased9patientsintheprophylaxisgroup, 3hadnottakenupinhalationsand3hadterminatedinhalati-ons prematurely, whereas of the surviving 36 patients 4 had neverinhaledlipAmBand19hadterminatedprematurely.In 4outof9deceasedpatientsinthetreatmentgroupand8of24 inthecontrolgroup,evidenceofpneumoniainthelastweeks beforedeathwasreportedinresponsetoourinquiries;however, course of disease and causes of death during this extended observation period were difficult to evaluate since many patients received further care outside of our hospital and,therefore,formanypatientsonlythelifestatusandlimitedclinicaldatawereavailable.TheexactdefinitionoftreatmentdelaysduetoinfectionsinAMLpatientsturnedoutto beverymuchpronetoindividualinterpretation,andtheanalysis of this point was therefore omitted although initially plannedintheprotocol.
Discussion
Inourstudy,wecouldconfirmthatprophylacticinhalations ofnebulizedlipAmBarefeasiblewithoutsignificanttoxicity. Aconcernisearlyterminationofprophylacticinhalationin asubstantialfractionofpatients;however,thisoccurredbecausepatientsconsideredthistreatmentunpleasant,andnot becauseoforgantoxicitygreaterthangradeI.Therefore,ifa clearclinicalbenefitcouldbeprovenandwereexplainedto patients,itislikelythatmostofthemwouldadheretosucha strategy. Hullard-Pulstinger/Holler/ Hahn/Andreesen/Krause trendforabetteroutcomeinpatientsadheringtotheinhalationschemeperprotocol.Secondly,theimprovedsurvivalof the AML cohort in our study is encouraging, although a significantbiasduetodifferentpatientcharacteristicsinthe interventionandcontrolgroupcannotberuledout.Taking thepositiveresultsofthelargerstudyofRijndersetal. [18] into account, inhalations of nebulized lipAmB may be an alternativetoprophylacticposaconazole [17] .Bothregimens shouldbecomparedinalargerrandomizedstudy.
